Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $1.3 million.

  • Agios Pharmaceuticals' Depreciation & Amortization (CF) fell 738.84% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.2 million, marking a year-over-year decrease of 842.03%. This contributed to the annual value of $5.2 million for FY2025, which is 842.03% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $1.3 million for Q4 2025, which was down 738.84% from $1.4 million recorded in Q3 2025.
  • Agios Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $2.5 million during Q1 2021, with a 5-year trough of $1.3 million in Q2 2025.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.7 million (2023), whereas its average is $1.8 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 2776.43% in 2023, then soared by 215.61% in 2025.
  • Agios Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $2.2 million in 2021, then fell by 17.62% to $1.8 million in 2022, then decreased by 22.66% to $1.4 million in 2023, then fell by 2.57% to $1.4 million in 2024, then decreased by 7.39% to $1.3 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.3 million for Q4 2025, versus $1.4 million for Q3 2025 and $1.3 million for Q2 2025.